Escudero-Vilaplana, Vicente http://orcid.org/0000-0003-4417-8321
Collado-Borrell, Roberto
del Monte-Millán, Maria
Hoyo-Muñoz, Angela
Gómez Martínez-Sagrera, Patricia
Revuelta-Herrero, Jose Luis
Marzal-Alfaro, Belen
Gonzalez-Haba, Eva
López-Tarruella Cobo, Sara
Jerez Gilarranz, Yolanda
Herranz, Ana
Sanjurjo, Maria
Martin, Miguel
Article History
Received: 21 October 2020
Accepted: 19 January 2021
First Online: 28 January 2021
Declarations
:
: The study was approved by the local ethics committee (study code MMJ-ITK-2013-01) and conducted in accordance with the ethical principles of the Declaration of Helsinki. Patients signed an informed consent before entering the study and for publication.
: Patients signed an informed consent before entering the study and for publication.
: Dr. Escudero-Vilaplana received support to continuing education/advisory fees from Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Ipsen Pharma, Janssen and Merck Sharp & Dohme, Novartis, and Pfizer, outside the submitted work.Dr. Collado-Borrell received support to continuing education/advisory fees from Boehringer ingelheim, Hoffmann-La Roche, Bristol-Myers Squibb, Janssen Cilag, and Pfizer, outside the submitted work.Dr. Marzal-Alfaro received support to continuing education/advisory fees from Roche, Abbvie, Pfizer, and Bayer Hispania, outside the submitted work.Dr. Gonzalez-Haba received support to advisory fees from Bayer, Bristol-Myers Squibb, and Novartis, outside the submitted work.Dr. Lopez-Tarruella Cobo has received consulting/advisory fees from Celgene, Novartis, Pierre Fabre, Pfizer, Roche, Astra-Zeneca, Eisai, Daiichi-Sankyo, and Lilly and speakers’ honoraria from Lilly, Novartis, and Pfizer, outside the submitted work.Dr. Jerez Gilarranz has a consultant or advisory role at Novartis, Pfizer, Roche, and AstraZeneca and has received speaker honoraria from Roche, Novartis, and AstraZeneca and travel grants from Roche, Novartis, Pfizer, and Teva.Dr. Herranz reported honorary/advisory fees from Astellas, Janssen, Kern, and Novartis, outside the submitted work.Dr. Martin has received research grants from Roche, PUMA, and Novartis; consulting/advisory fees from AstraZeneca, Amgen, Taiho Oncology, Roche/Genentech, Novartis, PharmaMar, Eli Lilly, PUMA, Taiho Oncology, Daiichi Sankyo, and Pfizer; and speakers’ honoraria from AstraZeneca, Lilly, Amgen, Roche/Genentech, Novartis, and Pfizer, outside the submitted work.
: N/A